Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
Integral Molecular’s technologies have contributed to scientific discoveries featured in 430+ peer-reviewed publications.
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.